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Abstract The imidazole antimycotics like ketoconazole, clotri- 
mazole, bifonazole, miconazole and CO, known as powerful in- 
hibitors of cytochrome P-450, are potent inhibitors of per- 
oxisomal phytanic acid a-oxidation to pristanic acid suggesting 
the possible involvement of the cytochrome P-450 mono-oxyge- 
nase system in this oxidation. In contrast to the inhibition of the 
oxidation of [1J4Clphytanic acid, [1-~4C]phytanoyi-CoA and 
[(2,3)-3I-I]phytanic acid, these drugs and CO have no effect on the 
oxidation of [1J4Cla-hydroxy phytanic acid indicating that these 
drugs and CO inhibit only the a-hydroxylation of phytanic acid. 
These studies using purified peroxisomes from liver and cultured 
human skin fibroblasts and Hep G2 cells clearly demonstrate that 
a-hydroxylation, an intermediate step in the a-oxidation of 
phytanic acid found to be impaired in Refsum Disease, is medi- 
ated by cytochrome P-450 containing enzyme. 
K, y words: Phytanic acid; Peroxisome (human); Antimycotics; 
C' 'tochrome P-450 
1. Introduction 
Phytanic acid (3,7,11,15-tetradecanoic acid), a saturated 
blanched-chain fatty acid, is present in trace amounts in 
h~ althy human subjects but accumulates to excessive amounts 
Jr, a number of neurological diseases [1,2]. It originates mainly 
flora dietary sources [1] with an estimated aily dietary intake 
oI 5~100 mg in humans. Due to the presence of the beta methyl 
g~ oup on its fatty acid chain it cannot be fl-oxidized, but it is 
a-oxidized [1] to its lower homologue, pristanic acid, which is 
then further catabolized by fl-oxidation. An abnormality in its 
c~ tabolism causes accumulation ofphytanic acid in tissues and 
b, ~dy fluids of patients with Refsum disease, Rhizomelic hon- 
d odysplasia punctata (RCDP) and in patients with defects in 
p,roxisomal biogenesis (e.g. Zellweger syndrome, Infantile 
R efsum Disease and Neonatal Adrenoleukodystrophy) [1,2]. 
Recently, we have established that in humans a-oxidation of 
p lytanic acid to pristanic acid takes place in peroxisomes [3-7]. 
Plytanoyl-CoA ligase is present in the peroxisomal limiting 
n embrane, and the enzyme system involved in the next three 
s~ ~ps (i.e. a-hydroxylation, dehydrogenation a d decarboxyla- 
t~ ~n) is present in the peroxisomal matrix [6]. Phytanoyl-CoA 
i~ synthesized on the cytoplasmic surface of the peroxisomal 
n embrane by phytanoyl-CoA ligase, a prerequisite for 
p lytanic acid's import into peroxisomes. Phytanoyl-CoA is 
t len converted to phytanic acid prior to its a-oxidation to 
pdstanic acid in the matrix ofperoxisomes [7]. The a-oxidation 
oi" phytanic acid to pristanic acid involves at least three steps: 
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a-hydroxylation to a-hydroxy phytanic acid, conversion to 2- 
ketophytanic a id and finally a-decarboxylation to a 19-carbon 
homologue, pristanic acid (Fig. 1). Based on the normal oxida- 
tion of a-hydroxy phytanic acid as compared to deficient oxida- 
tion of phytanic acid in monolayers of cultured skin fibroblasts 
from Refsum patients, Steinberg and associates [8] have sug- 
gested that the defect in the a-oxidation of phytanic acid in 
Refsum may be in the a-hydroxylation step. By using purified 
peroxisomes from cultured skin fibroblasts of control and pa- 
tients with Refsum disease we have demonstrated that a-oxida- 
tion of phytanic acid to pristanic acid is defective in per- 
oxisomes of Refsum disease [5]. However, at present very little 
is known about he biochemical characteristics of phytanic acid 
a-hydroxylase, which appears to be a key enzyme of phytanic 
acid catabolic pathway. In this manuscript, we report hat im- 
idazole antimycotics, potent inhibitors of cytochrome P-450, 
and CO inhibit the oxidation of phytanic acid but not of a- 
hydroxy phytanic acid demonstrates the involvement of cyto- 
chrome P-450 in the a-hydroxylation, the step which is defec- 
tive in Refsum disease. 
2. Materials and methods 
Nycodenz was obtained from Accurate Chemical and Scientific 
Corp., Westbury, NY. ATP and CoASH were purchased from P-L 
Biochemicals, Milwaukee, WI. Cytochrome c,c~-cyclodextrin and FAD 
were purchased from Sigma Chemical Co, MI. [1-~4C]Phytanic acid (55 
mCi/mmol) was purchased from Amersham International, Arlinghton 
Heights, IL. [l-~4C]Phytanoyl-CoA was synthesized as described [9]. 
[(2,3)-3H]Phytanic acid was synthesized from [(2,3)-3H]dihydrophytol 
as described by Zenger-Hain et al. [10]. [1 -~4C]~-hydroxy phytanic acid 
was synthesized from [1-~4C]phytanic acid by the treatment of oxalyl 
chloride and bromine followed by alkaline hydrolysis as mentioned by 
Skjeldal and Stokke [11]. 
2.1. Isolation oJ peroxisomes from human liver 
Peroxisomes from human liver were isolated according to the proce- 
dures described previously [4]. Briefly, the liver homogenate was first 
fractionated by differential centrifugation to prepare the light mito- 
chondrial fraction, the 'lambda' fraction [12], and the peroxisomes from 
the lambda fraction were prepared by isopycnic equilibrium centrifuga- 
tion in continuous Nycodenz gradients. Tubes (39 ml) for a Beckman 
JV-20 rotor were layered with 4 ml of 55% (w/v) Nycodenz and 28 ml 
of a continuous gradient consisting Of 0 50% (w/v) Nycodenz in ho- 
mogenization medium. Gradient fractions were analyzed for the follow- 
ing subcellular markers: cytochrome c oxidase for mitochondria [13], 
NADH cytochrome c reductase for microsomes [14] and catalase for 
peroxisomes [15]. Protein concentration was determined by the proce- 
dure of Bradford [16]. The three fractions with highest catalase activity 
from the gradient were pooled, dialyzed against he homogenization 
buffer for 1 h to lower the concentration of Nycodenz and used for 
further studies. 
2.2. Activation and oxidation of fatty acids 
The activities for phytanoyl-CoA ligase were measured as described 
previously [5 7]. Briefly, the reaction mixture in 0.25 ml contained 
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12/.tM [1-14C]phytanic acid, 50 mM KCI, 5mM MgCI2, 50/IM CoASH, 
10 mM ATE and 30 mM MOPS-HC1 buffer, pH 7.8. The o-oxidation 
of [1J4C]phytanic acid and [1J4C]~-hydroxy phytanic acid was meas- 
ured as liberated J4CO2 as described previously [3,4]. Briefly, the reac- 
tion volume of 0.25 ml contained 12JAM fatty acid, 30 mM KCI, 5 mM 
MgCI2, 50/JM CoASH, 10 mM ATE 0.25 mM NADPH, 0.17 mM 
FAD and 20 mM MOPS-HC1 buffer, pH 7.8. The assay for oxidation 
of [(2,3)JH]phytanic acid was done essentially as described by Zenger- 
Hain et al. [10]. 
3. Results 
3.1. Effect of imidazole derivatives on at-oxidation of phytanic 
acid by human liver peroxisomes 
Peroxisomes were purified from human liver by differential 
and Nycodenz density gradient centrifugation, procedures rou- 
tinely used in the laboratory [4-7]. Peroxisomes in the per- 
oxisomal peak fraction (density of 1.27 gm/ml) had approxi- 
mately 95% purity with minor contamination by mitochondria 
(1.0-1.5%) and microsomes (2.8-3.5%) as protein. Percent pu- 
rity of peroxisomal fractions was calculated according to the 
method described by Fujiki et al. [17]. Fig. 2 shows the effects 
of different concentrations of the imidazole antimycotics on the 
activity of phytanic acid at-oxidation in human liver per- 
oxisomes. These drugs were able to markedly inhibit per- 
oxisomal at-oxidation of phytanic acid in a concentration-de- 
pendent manner, and at a concentration of 5/ JM inhibited 
at-oxidation of phytanic acid in the range of 30 to 50%. Among 
the four imidazole derivatives used, ketoconazole was seen to 
be the most potent in inhibiting at-oxidation. 
To identify the metabolic step in the at-oxidation of phytanic 
acid that is inhibited by imidazole antimycotics we examined 
the effect of these compounds on the activation of phytanic acid 
by phytanoyl-CoA ligase (Table 1) and oxidation of the sub- 
strates for different steps of the at-oxidation pathway (Tables 
2 and 3). The activation of phytanic acid to phytanoyl-CoA by 
phytanoyl-CoA ligase is the first and obligatory step in its 
catabolism in intact peroxisomes [6], but these drugs had no 
effect on phytanoyl-CoA ligase activity (Table 1). Table 2 
shows the effect of these antimycotics and carbon monoxide 
(CO) on the oxidation of [1J4C]phytanic acid, [1-14C]phy- 
tanoyl-CoA, [(2,3)JH]phytanic acid and [1-14C]at-hydroxy - 
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Fig. 1. Pathways of phytanic acid catabolism. 
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Fig. 2. Effect of different imidazole antimycotics on the o-oxidation 
[1-14C]phytanic a id by human liver peroxisomes. Peroxisomes were 
isolated from human liver as mentioned in section 2. Peroxisomes were 
preincubated for 15 min with different amounts of imidazole deriva- 
tives. Data presented is the average of two separate determinations. 
phytanic acid, which are substrates for different catabolic steps 
in the metabolism of phytanic acid. All these drugs at a concen- 
tration of 20 uM inhibited the oxidation of [1-IaC]phytanic a id 
and [1-14C]phytanoyl-CoA by about 80 to 90%. Consistent with 
the fact that these imidazole antimycotics are potent inhibitors 
of cytochrome P-450 (P-450), these oxidations were also inhib- 
ited by CO in the range of 60 to 65%, suggesting that at least 
one of the steps of phytanic acid alpha-oxidation is mediated 
by a cytochrome P-450 related hemoprotein. The release of [3H] 
from [(2,3)-3H]phytanic a id as 3H20 [10] provides a measure 
of at-hydroxylation since the 3H is lost from the at-position in 
this process (Fig. 1). The imidazole antimycotics were potent 
inhibitors of the release of 3H from [(2,3)-3H]phytanic a id 
(Table 2). However, in contrast o the potent inhibition of 
at-oxidation of [(2,3)-3H]phytanic acid, these drugs and CO had 
no effect on the oxidation of [1-14C]at-hydroxyphytanic c d 
indicating that they specifically inhibit the at-hydroxylation step 
of phytanic acid catabolic pathway indicating that this step is 
mediated by a cytochrome P-450 related hemoprotein. 
Table 1 
Effect of different imidazole antimycotics on activation of phytanic acid 
by human liver peroxisomes 
Inhibitors 
(20/aM) 
Activation (Phytanoyl-CoA ligase) 
(nmol/min/mg protein) 
Control 7.54 + 1.22 
Ketoconazole 7.37 + 0.95 
Clotrimazole 7.70 + 1.52 
Miconazole 7.43 _+ 1.46 
Bifonazole 7.66 + 0.95 
Human liver peroxisomes were preincubated with different imidazole 
antimycotics for 15 min and phytanoyl-CoA ligase activity were meas- 
ured as mentioned in the methods ection. Results were expressed as 
mean + S.D. of three different experiments. 
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Table 2 
Effect of imidazole derivatives and carbon monoxide (CO) on phytanic acid ~-oxidation by human liver peroxisomes 
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InMbitors Percent activity 
[lJ4C]Phytanic acid [1-~4C]Phytanoyl-CoA [(2,3)3H]Phytanic ac id  [1-~4C]c~-Hydroxy phytanic acid 
Keloconazole (20 pM) 10.5 + 1.6 9.2 +_ 1.9 16.6 + 2.9 82.9 + 10.2 
Ck~trimazole (20 pM) 11.3 + 2.1 9.7 + 1.2 15.8 + 1.4 86.4 + 7.8 
Miconazole (20 pM) 12.8 + 1.9 11.9 + 2.5 17.2 +_ 2.8 89.8 + 11.3 
Bil,mazole (20 pM) 13.2 + 2.8 12.4 + 1.8 17.6 + 3.1 90.6 + 8.9 
CO 37.3 -+ 5.2 38.6 _+ 4.5 41.7 _+ 6.2 92.6 + 12.5 
Ht~man liver peroxisomes were preincubated with different imidazole antimycotics for 15 min. For carbon monoxide treatment, peroxisomes were 
bu!~bled with CO for 3 min followed by O2/CO2 (95 : 5, v/v) for 30 s. Control peroxisomes were treated with N2 in the same way with CO. Oxidations 
were carried out as mentioned in section 2. Results are expressed asmean +_ S.D. of three different experiments. 100% activities represent 48.6 + 
6,1 pmol/h/mg for [1-t4C]phytanic acid, 45.9 + 5.8 pmol/h/mg for [l-14C]phytanoyl-CoA, 31.6 +_ 5.3 pmol/h/mg for [(2,3)-3H]phytanic acid and 
34 ] + 4.8 pmol/h/mg for [1-t4C]c~-hydroxy ph tanic acid. 
3... Effect of imidazole derivatives and CO on phytanic acid 
oxidation by human skin fibroblast and human HepG2 cells 
~ince imidazole antimycotics inhibit ~t-oxidation fphytanic 
acid in peroxisomes i olated from human liver, we also exam- 
incd the effect of ketoconazole on phytanic acid oxidation by 
cultured human skin fibroblasts and human HepG2 cells. The 
cuitured cells were treated with ketoconazole 20~tM for 15 min 
and then examined for their ability to metabolize phytanic acid 
derivatives (Table 3). Consistent with the inhibitions found on 
p~ytanic acid oxidation in human liver isolated peroxisomes, 
th: oxidation of [(2,3)-3H]phytanic a id, [1-~4C]phytanic a id 
arid [1-~4C]phytanoyl-CoA in both the cell lines was inhibited 
in the range of 75 to 85% in the presence of ketoconazole; 
whereas the oxidation of [1-~4C]~-hydroxy phytanic acid re- 
in tined unaffected. These studies on human liver isolated per- 
o~isomes and intact human cell lines (cultured skin fibroblasts 
arid HepG2) clearly demonstrate that a P-450-1ike hemoprotein 
is involved in the ~-hydroxylation f phytanic acid in per- 
o,, isomes. 
4. Discussion 
Recent studies have provided conclusive vidence for the 
in eolvement ofperoxisomes inthe cz-oxidation of phytanic acid 
in humans [3-7]. Here we describe the imidazole antimycotics 
a,, inhibitors of peroxisomal phytanic acid ~-oxidation, with 
k~ toconazole being the most potent. Inhibition of the oxidation 
ol phytanic acid or phytanoyl-CoA by imidazole antimycotics 
mtd CO as compared to the lack of such an effect on phytanoyl- 
C )A ligase activity and oxidation of c~-hydroxyphytanic acid 
i~dicates that the phytanic acid ct-hydroxylase is a cytochrome 
P 450-like hemoprotein. Characterization a d complete under- 
st mding of the mechanism of~-hydroxylation f phytanic acid 
is important since phytanic acid accumulates in pathognomic 
amounts in tissues and body fluids of patients with Refsum 
Disease due to an abnormality in the ct-hydroxylation of
phytanic acid [1,2]. Activation and transport of phytanic acid 
are membrane phenomena; whereas other steps of ~-oxidation, 
including the ~-hydroxylation step, take place in the per- 
oxisomal matrix [6] suggesting that the phytanic acid alpha- 
hydroxylase, which is a cytochrome P-450 like hemoprotein, is 
a peroxisomal matrix component. Although cytochrome P-450 
proteins have not been purified from peroxisomes so far, a 
number of lines of evidence indicate the possible presence of a 
P-450 monooxygenase system in peroxisomes. The conversion 
of cholesterol to propionic acid [18], hydroxylation of 3-~t, 7-~, 
12-c~-trihydroxy, 5-fl cholestane tocholestanetetrol [19], and the 
synthesis of cholesterol from mevalonic acid [20] by purified 
peroxisomes supports the presence of P-450 monooxygenase 
systems in peroxisomes. Additionally, the presence of cyto- 
chrome bs, NADH cytochrome c (bj  reductase and NADPH 
cytochrome P-450 reductase in peroxisomes [21] has been de- 
scribed recently. Moreover, we have identified proteins that 
react with antibodies against P-450 2El and P-450 IAI in rat 
liver peroxisomes [22]. 
Ketoconazole and other imidazole derivatives have long 
been used as effective therapeutic agents in the treatment of 
mycotic infections [23]. At a single oral dose of 200 rag/day, 
ketoconazole inhibits the P-450 enzyme-dependent biosynthe- 
sis of ergosterol from lanosterol in fungi, leading to their even- 
tual destruction [23,24]. Because ketoconazole can be adminis- 
tered orally and has a broad-spectrum of activity against both 
superficial and deep mycoses, this imidazole derivative has be- 
come widely used as an antifungal agent [23]. In recent years 
it has also become apparent that ketoconazole also inhibits 
steroidogenesis [23]. In high doses (400 mg three times a day), 
I. ~ble 3 
E'fect of ketoconazole on s-oxidation of phytanic acid by cultured skin fibroblasts and human Hep G2 cells 
C :lls Rate of Oxidation (pmol/h/mg protein) 
Ketocanazole [1-14C]Phytanic [1-~4C]Phytanoyl - [(2,3)3H] Phytanic [1 -14C]0~ - 
(20/~M) acid CoA acid hydroxy phytanic acid 
S<in Fibroblasts without 16.8 + 3.2 18.5 _+ 2.3 13.2 + 1.9 10.9 + 2.4 
with 2.92 + 0.52 2.87 + 0.41 3.05 _+ 0.55 9.56 +_ 1.85 
HepG2 without 22.3 + 2.5 20.9 _+ 3.8 18.6 + 2.8 14.1 + 2.3 
with 3.1 + 0.2 3.2 + 0.4 4.3 + 0.5 12.2 + 1.8 
Oxidations were carried out in cells uspended in Hank's Balanced Salt Solution (HBSS) as mentioned inthe methods section. Cells were preincubated 
ith Ketoconazole for 15 min. 
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it inhibits P-450-dependent biosynthesis of testicular and adre- 
nal androgens, and therefore is applied for the treatment of 
diseases such as advanced prostatic ancer, precocious puberty, 
hirsuitism and Cushing's yndrome [23,25]. However, its sev- 
eral side effects like gastrointestinal disturbances, muscle fa- 
tigue, dry skin, mucosa, nail dystrophy and symptoms ofhyper- 
vitaminosis A restrict its routine use in these diseases [23]. The 
inhibition of phytanic acid oxidation by these drugs has identi- 
fied another possible side effect of imidazole antimycotics. De- 
tailed information regarding the effects of these drugs on mam- 
malian biochemical pathways are important in terms of their 
clinical utility. Accumulation of phytanic acid in Refsum Dis- 
ease is neurological degeneration a d retinal changes consistent 
with retinitis pigmentosa [1,2]. The morphological changes im- 
ilar to the ones observed in Refsum Disease in retinal pigment 
epithelial cells in an in vitro assay system when these cells were 
incubated with phytanic acid at concentration comparable to 
the levels found in affected humans upport a role of excessive 
phytanic acid in cellular toxicity [26]. 
In summary, we have demonstrated that imidazole antimy- 
cotics are potent inhibitors of peroxisomal phytanic acid ~- 
oxidation, and that peroxisomal phytanic acid 0~-hydroxylase 
is a cytochrome P-450 related hemoprotein. 
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